Last updated: September 3, 2026
PF-05221304 is an oral, liver-directed acetyl-CoA carboxylase (ACC) inhibitor developed by Pfizer for nonalcoholic steatohepatitis (NASH), now termed metabolic dysfunction-associated steatohepatitis (MASH). Clinical studies showed meaningful reductions in hepatic fat, but the program faced the class risk of increased triglycerides and LDL cholesterol. PF-05221304 is not an FDA-approved medicine, has no Orange Book listing, and does not appear to be an active Pfizer commercial-stage asset. Its standalone commercial outlook is therefore limited unless Pfizer or a partner restarts development.
What is PF-05221304 and how does it work?
PF-05221304 inhibits ACC1 and ACC2, enzymes involved in fatty-acid synthesis and oxidation. The intended effect is to reduce de novo lipogenesis, lower liver fat, and improve steatohepatitis.
| Attribute |
PF-05221304 |
| Developer |
Pfizer |
| Drug class |
Liver-directed ACC inhibitor |
| Primary target |
Acetyl-CoA carboxylase 1 and 2 |
| Intended indication |
NASH/MASH with liver fibrosis |
| Administration |
Oral |
| FDA approval |
None |
| Biologic or small molecule |
Small molecule |
| Biosimilar exposure |
None |
| Orange Book status |
No listed product |
| Public clinical stage |
Phase 2 evidence |
| Current commercial status |
No disclosed launch program |
ACC inhibition is biologically attractive because excess hepatic lipogenesis contributes to steatosis and inflammation. The development challenge is systemic lipid disruption. ACC inhibition can increase circulating triglycerides and LDL cholesterol, requiring lipid-lowering treatment or careful patient selection.
What clinical development did PF-05221304 complete?
Pfizer evaluated PF-05221304 in early and mid-stage studies involving patients with fatty liver disease and NASH. The central clinical signal was a reduction in liver fat measured by magnetic resonance imaging-based methods.
A Pfizer-sponsored Phase 2 study evaluated PF-05221304 in participants with NASH. The clinical program examined multiple dose levels and assessed liver fat, liver enzymes, lipids, and safety outcomes. Public trial records identify PF-05221304 as an investigational treatment rather than an approved or registration-stage product. [1]
Clinical development timeline
| Period |
Development event |
| Pre-2020 |
Pfizer advances PF-05221304 as a liver-directed ACC inhibitor |
| 2020-2021 |
Phase 2 studies evaluate hepatic fat reduction and metabolic safety |
| 2021 onward |
Public development visibility declines |
| 2023-2024 |
Pfizer pipeline disclosures do not identify PF-05221304 as a major active late-stage program |
| Current status |
No FDA filing, approval, commercial launch, or disclosed pivotal program |
Available clinical evidence supports pharmacologic activity, but it does not establish fibrosis improvement, prevention of cirrhosis, or a regulatory path to approval.
How effective was PF-05221304 in NASH or MASH?
PF-05221304 reduced hepatic fat in clinical studies. The effect was directionally consistent with the mechanism and with results seen for other ACC inhibitors. Improvements in liver enzymes and steatosis were reported, but the most important regulatory endpoint in MASH is usually fibrosis improvement without worsening of steatohepatitis, or resolution of steatohepatitis with no worsening of fibrosis.
The publicly available PF-05221304 record does not establish a confirmed histology-based registration result. That distinction is material. A large reduction in MRI-measured liver fat can support proof of mechanism, but it does not guarantee approval.
Principal efficacy strengths
- Oral dosing.
- Direct reduction of hepatic de novo lipogenesis.
- Demonstrated reduction in liver fat.
- Potential combination use with statins, incretin therapies, or other MASH agents.
Principal development weaknesses
- No established fibrosis outcome.
- Limited late-stage evidence.
- Class-related triglyceride and LDL increases.
- Potential need for combination lipid management.
- Strong competition from approved and late-stage MASH therapies.
What safety issues affected PF-05221304 development?
The main safety and commercial concern is dyslipidemia. ACC inhibition can produce increases in triglycerides and LDL cholesterol, which may offset some of the cardiometabolic benefit expected from reducing liver fat.
Pfizer tested PF-05221304 with lipid-management strategies, including statin treatment in related clinical development. This approach could improve the benefit-risk profile, but it also adds treatment complexity and makes the drug less attractive as a simple monotherapy.
The relevant safety questions for any restart would include:
- Whether triglyceride increases are dose-dependent.
- Whether LDL elevations are fully controlled with statins.
- Whether lipid changes translate into cardiovascular risk.
- Whether patients with advanced fibrosis tolerate long-term treatment.
- Whether combination therapy improves fibrosis outcomes without cumulative toxicity.
What is the FDA regulatory status of PF-05221304?
PF-05221304 has no FDA approval, no approved label, and no publicly identified New Drug Application. It has not received an FDA Complete Response Letter because no public approval application is associated with the compound.
| FDA and regulatory item |
Status |
| Investigational New Drug application |
Clinical development implied; public filing details unavailable |
| Breakthrough Therapy designation |
No public designation identified |
| Fast Track designation |
No public designation identified |
| New Drug Application |
None publicly identified |
| FDA approval |
None |
| Approved indication |
None |
| REMS |
None |
| Commercial label |
None |
The approval of resmetirom, marketed as Rezdiffra, changed the competitive standard for MASH drugs. The FDA approved resmetirom in March 2024 for adults with noncirrhotic NASH with moderate-to-advanced liver fibrosis, in conjunction with diet and exercise. [2] PF-05221304 would now need to demonstrate a clinically differentiated profile against an approved therapy rather than compete only with investigational drugs.
What patents protect PF-05221304?
PF-05221304 is a Pfizer development code, not a patent identifier. Pfizer likely pursued protection through compound, pharmaceutical composition, therapeutic-use, and manufacturing patent families. The public drug code alone does not establish the complete patent estate or confirmed expiry dates.
Because PF-05221304 has no approved product, there is no FDA Orange Book patent listing. The absence of an Orange Book listing does not mean the compound lacks patent protection. It means that no approved drug product is available for FDA listing under the Orange Book framework.
Likely patent categories
| Patent category |
Commercial purpose |
| Composition of matter |
Protects the PF-05221304 chemical entity and related compounds |
| Pharmaceutical composition |
Protects dosage forms and excipient combinations |
| Method of treatment |
Covers treatment of NASH, fatty liver disease, dyslipidemia, or fibrosis |
| Combination therapy |
May cover use with statins or other metabolic agents |
| Manufacturing process |
Protects synthesis, intermediates, crystallinity, or purification |
| Selection or formulation claims |
May protect particular doses, salts, polymorphs, or delivery characteristics |
No confirmed Orange Book expiry date or publicly validated PF-05221304 patent term should be used in a launch model. Any future restart would depend on the surviving patent family, patent-term adjustment, patent-term extension eligibility, and the scope of claims that remain enforceable.
When would PF-05221304 lose exclusivity?
PF-05221304 has no approved exclusivity period because it has no approved indication. FDA regulatory exclusivities such as five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, and seven-year orphan-drug exclusivity have not been granted for this compound.
Patent exclusivity is separate from FDA exclusivity. If Pfizer obtained composition-of-matter patents, those patents could remain relevant even without approval. Their practical value depends on whether Pfizer resumes clinical development and whether the claims cover the final clinical candidate.
Exclusivity position
| Exclusivity type |
PF-05221304 status |
| New chemical entity exclusivity |
Not started |
| Orphan-drug exclusivity |
Not identified |
| Pediatric exclusivity |
Not identified |
| Patent-term extension |
Not available without an approved product |
| Orange Book-listed patents |
None |
| Generic substitution |
Not applicable |
Are there Paragraph IV challenges or patent litigation?
No publicly identified Paragraph IV litigation or ANDA challenge affects PF-05221304. Paragraph IV litigation generally requires an approved reference drug with Orange Book-listed patents. PF-05221304 has neither.
No major public patent settlement agreement, license dispute, or infringement case involving a PF-05221304 generic challenger has been identified. The absence of litigation reflects the compound’s development status rather than proof that all patent risks have expired.
Which companies compete with PF-05221304?
PF-05221304 competes with three groups: approved MASH products, late-stage metabolic therapies, and other ACC inhibitors.
| Company |
Asset |
Mechanism or class |
Competitive position |
| Madrigal Pharmaceuticals |
Resmetirom |
Thyroid hormone receptor beta agonist |
First FDA-approved MASH therapy |
| Novo Nordisk |
Semaglutide |
GLP-1 receptor agonist |
Strong weight-loss and metabolic profile; MASH development |
| 89bio |
Pegozafermin |
FGF21 analog |
Fibrosis and steatohepatitis development |
| Akero Therapeutics |
Efruxifermin |
FGF21 analog |
Advanced-stage MASH program |
| Viking Therapeutics |
VK2809 |
Liver-directed thyroid hormone receptor beta agonist |
Liver-fat and metabolic development |
| Gilead Sciences |
Firsocostat |
ACC inhibitor |
Class comparator; development challenges include lipid effects |
| InventisBio and others |
Small-molecule metabolic agents |
Multiple mechanisms |
Competitive oral-therapy pipeline |
The most direct comparator is firsocostat, another ACC inhibitor. The class has shown liver-fat reduction but has struggled to translate that effect into a clean long-term clinical and regulatory profile. PF-05221304 would need either superior lipid tolerability or a combination strategy that produces fibrosis benefit.
How strong is the PF-05221304 patent estate?
The patent estate is commercially unproven rather than clearly weak. A composition-of-matter patent can provide meaningful protection, but its value falls sharply when clinical development stops. Method-of-use claims are more vulnerable to validity and infringement challenges, particularly when the indication and dosing regimen overlap with prior art.
Patent-strength assessment
| Factor |
Assessment |
| Composition protection |
Potentially meaningful if unexpired and claim scope is narrow enough to cover the candidate |
| Formulation protection |
Likely secondary because the product is an oral small molecule |
| Method-of-use protection |
Potentially vulnerable to prior-art and obviousness attacks |
| Manufacturing protection |
Useful as a barrier to process replication, but rarely sufficient alone |
| Orange Book leverage |
None without approval |
| Litigation leverage |
Low at present because there is no commercial launch |
| Partnering value |
Dependent on clinical reactivation and remaining patent term |
What market could PF-05221304 address?
The MASH market has substantial patient volume but is difficult to monetize because diagnosis rates are low, fibrosis staging is expensive, and treatment may require long-term monitoring. The approval of resmetirom created an initial commercial market, but it also established a safety and efficacy benchmark.
A successful PF-05221304 launch would likely require:
- Demonstrated fibrosis improvement.
- A favorable lipid profile or reliable statin combination.
- An oral regimen with simple dosing.
- Competitive pricing against resmetirom and future incretin-based treatments.
- Use in patients with obesity, diabetes, or dyslipidemia.
- Evidence of benefit in combination with GLP-1 or other MASH therapies.
Scenario-based revenue outlook
| Scenario |
Development assumption |
Commercial result |
| Base case |
Pfizer does not restart the program |
No product revenue |
| Reactivation case |
Partner or Pfizer conducts a new Phase 2 study |
Limited value before pivotal proof |
| Approval case |
Positive fibrosis data and manageable dyslipidemia |
Potential niche or combination product |
| Best case |
Oral ACC inhibitor with superior lipid control and combination efficacy |
Multi-billion-dollar category opportunity, but low probability for PF-05221304 specifically |
The base-case revenue forecast is zero because no launch program or regulatory filing is publicly established. A multi-billion-dollar MASH market forecast applies to the therapeutic category, not to PF-05221304. Resmetirom’s approval validates commercial demand, but it does not validate PF-05221304’s probability of reaching market.
What generic launch risks exist for PF-05221304?
There is no immediate generic launch risk because PF-05221304 is not approved and has no reference listed drug. If development resumes and the product is approved, the principal risks would arise from:
- Paragraph IV challenges to composition patents.
- Method-of-use challenges based on MASH prior art.
- Generic development of alternative salts, polymorphs, or formulations.
- Patent-term expiry before broad market penetration.
- Off-label competition from approved metabolic drugs.
Unlike biologics, PF-05221304 would not face a biosimilar pathway. It would face conventional generic-drug competition under an ANDA pathway after relevant patent and regulatory exclusivity periods expire.
How does PF-05221304 compare with resmetirom?
Resmetirom has a decisive regulatory advantage because it is approved for noncirrhotic MASH with moderate-to-advanced fibrosis. PF-05221304 has a mechanistic advantage as a direct inhibitor of hepatic fatty-acid synthesis, but it lacks late-stage evidence and approval.
| Issue |
PF-05221304 |
Resmetirom |
| FDA status |
Investigational |
Approved |
| Mechanism |
ACC inhibition |
THR-beta agonism |
| Liver-fat reduction |
Demonstrated in clinical studies |
Demonstrated |
| Fibrosis approval |
None |
Yes |
| Lipid concern |
Triglyceride and LDL increases associated with class |
Lipid effects are part of clinical profile |
| Patent position |
No Orange Book listing |
Approved-product patent estate |
| Commercial readiness |
Low |
Established |
| Generic risk |
Not currently applicable |
Future ANDA and patent challenges possible |
Key Takeaways
- PF-05221304 is an oral Pfizer ACC inhibitor developed for NASH/MASH.
- Clinical studies demonstrated liver-fat reduction, supporting proof of mechanism.
- The program did not produce a public FDA filing or approval.
- Triglyceride and LDL increases are the principal class-related development concern.
- PF-05221304 has no Orange Book listing, FDA exclusivity period, or identified Paragraph IV litigation.
- The patent estate may include composition, method-of-use, formulation, and manufacturing claims, but confirmed expiry dates are not established by the drug code alone.
- Resmetirom’s 2024 approval materially raises the evidence standard for any PF-05221304 restart.
- The base-case commercial forecast is zero revenue unless Pfizer or a partner reactivates the program.
- The compound could retain strategic value as a combination therapy if it demonstrates fibrosis benefit and improved lipid management.
FAQs
Is PF-05221304 the same drug as resmetirom?
No. PF-05221304 is an ACC inhibitor. Resmetirom is a thyroid hormone receptor beta agonist and is FDA-approved for MASH with moderate-to-advanced fibrosis.
Was PF-05221304 discontinued?
Public disclosures do not identify PF-05221304 as an active Pfizer commercial or late-stage program. Its publicly visible development has declined after Phase 2 work.
Does PF-05221304 have a generic version?
No. PF-05221304 is not approved, and no generic product can be substituted for it.
Could PF-05221304 be combined with a statin?
Yes. Lipid-lowering combination treatment was clinically relevant because ACC inhibition can increase triglycerides and LDL cholesterol. A statin combination could be part of any future development strategy.
Is PF-05221304 relevant to obesity-drug investors?
Potentially, but only as a discontinued or inactive MASH asset unless development resumes. Its investment value depends on reactivation, remaining patent life, and evidence that ACC inhibition improves fibrosis without unacceptable lipid effects.
References
- ClinicalTrials.gov. (n.d.). Study of PF-05221304 in participants with nonalcoholic steatohepatitis. U.S. National Library of Medicine. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (2024). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
- Pfizer Inc. (2023). Annual report and pipeline disclosures. https://www.pfizer.com/investors/financial-reports
- Younossi, Z. M., et al. (2021). Global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 74(2), 1014-1029.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm